{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:03:00Z","timestamp":1789448580395,"version":"build-2803163510"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Concurrent chemoradiotherapy (cCRT) followed by consolidation immunotherapy constitutes the current standard of care for unresectable locally advanced non\u2013small cell lung cancer (LA-NSCLC). Despite this approach, a substantial proportion of patients experience disease progression, underscoring the need for novel therapeutic strategies. This study was undertaken to evaluate whether induction chemoimmunotherapy administered prior to definitive CRT can improve clinical outcomes. We evaluated the efficacy and safety of induction chemoimmunotherapy followed by CRT in patients with unresectable LA-NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort of patients with unresectable LA-NSCLC treated at the Affiliated Cancer Hospital of Harbin Medical University between January 2020 and October 2022 was analyzed. Patients were classified according to receipt of induction immunochemotherapy into the I-CRT group (n=62) and the CRT group(n=142). Inverse probability of treatment weighting (IPTW) was applied to adjust for baseline confounding. Assess overall survival (OS), progression- free survival (PFS), and safety in the two patient groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After IPTW adjustment, the weighted cohort comprised 286 patients (I-CRT, 104; CRT, 182). In IPTW weighted analyses, median OS was significantly longer in the I-CRT group than in the CRT group (38.8 months vs 23.9 months; hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.28 to 0.77; p = 0.003). Median PFS was also improved with induction chemoimmunotherapy (18.1 months vs 11.7 months; HR, 0.61; 95% CI, 0.39 to 0.95; p=0.028). The overall incidence of treatment-related adverse events (TRAE) was comparable between groups, with the exception of hyperthyroidism, which occurred more frequently in the I-CRT cohort (16. 1% vs 5.6%; p=0.025). Hematologic toxicity was the most common grade \u22653 TRAE. Collectively, the safety profile was acceptable and manageable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Induction chemoimmunotherapy administered prior to CRT confers significant and durable improvements in PFS and OS, with a manageable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1902715","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:27:37Z","timestamp":1789446457000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety analysis of induction therapy for unresectable locally advanced non-small-cell lung cancer: a retrospective study based on IPTW"],"prefix":"10.3389","volume":"16","author":[{"given":"Tianlong","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Harbin Medical University Cancer Hospital","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Harbin Medical University Cancer Hospital","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Harbin Medical University Cancer Hospital","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Harbin Medical University Cancer Hospital","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Harbin Medical University Cancer Hospital","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Harbin Medical University Cancer Hospital","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Harbin Medical University Cancer Hospital","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.04.001","article-title":"Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer","volume":"66","author":"Skrzypski","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40425-018-0382-2","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)","volume":"6","author":"Brahmer","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.10.005","article-title":"Patterns of failure, low-volume relapse, and subsequent ablative management in locally advanced non-small cell lung cancer treated with definitive chemoradiation and consolidation immune checkpoint inhibitors","volume":"118","author":"Friedes","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12964-023-01139-8","article-title":"Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations","volume":"21","author":"Wu","year":"2023","journal-title":"Cell Commun Signal"},{"key":"B8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41571-025-01080-4","article-title":"Unresectable stage III non-small-cell lung cancer: state of the art and challenges","volume":"23","author":"Remon","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1022042","article-title":"Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.1897","article-title":"Atezolizumab before and after chemoradiation for unresectable stage III non-small cell lung cancer: A phase II nonrandomized controlled trial","volume":"10","author":"Ross","year":"2024","journal-title":"JAMA Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/art.43417","article-title":"Efficacy of Telitacicept in childhood-onset systemic lupus erythematosus: A prospective multicenter cohort study with inverse probability of treatment weighting -adjusted comparison to a historical control group treated with Belimumab","volume":"8","author":"Luo","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001053","article-title":"Intersphincteric resection following robotic-assisted versus laparoscopy-assisted total mesorectal excision for middle and low rectal cancer: a multicentre propensity score analysis of 1571 patients","volume":"110","author":"Guo","year":"2024","journal-title":"Int J Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.0130","article-title":"Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04","volume":"33","author":"Ahn","year":"2015","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.3569","article-title":"Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B","volume":"25","author":"Vokes","year":"2007","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: The phase 2 KEYNOTE-799 nonrandomized trial","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00036","article-title":"Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung cancer: The phase III PACIFIC-2 study","volume":"43","author":"Bradley","year":"2025","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.07.005","article-title":"CheckMate 73L: A phase 3 study comparing nivolumab plus concurrent chemoradiotherapy followed by nivolumab with or without ipilimumab versus concurrent chemoradiotherapy followed by durvalumab for previously untreated, locally advanced stage III non-small-cell lung cancer","volume":"23","author":"De Ruysscher","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-439","article-title":"Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers","volume":"11","author":"Deng","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.501","article-title":"Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non-small cell lung cancer: a multi-institutional retrospective cohort study","volume":"5","author":"Wu","year":"2024","journal-title":"MedComm (2020)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.09.050","article-title":"Pneumonitis after chemoradiotherapy and adjuvant durvalumab in stage III non-small cell lung cancer","volume":"118","author":"Edwards","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00627","article-title":"Selective personalized radioimmunotherapy for locally advanced non-small-cell lung cancer trial (SPRINT)","volume":"42","author":"Ohri","year":"2024","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3600","article-title":"Fraction dose escalation of hypofractionated radiotherapy with concurrent chemotherapy and subsequent consolidation immunotherapy in locally advanced non-small cell lung cancer: A phase I study","volume":"30","author":"Zhou","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110121","article-title":"Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma","volume":"193","author":"Corrigan","year":"2024","journal-title":"Radiother Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1902715\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:27:38Z","timestamp":1789446458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1902715\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":26,"alternative-id":["10.3389\/fonc.2026.1902715"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1902715","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1902715"}}